Abstract
Glucocorticoids (GCs) are used to treat different inflammatory and autoimmune diseases due to their anti-inflammatory and immunoregulatory properties. However, GC may lead to the development of many adverse reactions (ARs): hypertension, diabetes mellitus, lipid metabolic disturbances, sleep apnea, osteoporosis, myopathy, and coagulation and fibrinolysis disorders, which are components of the Itsenko – Cushing syndrome. ARs induced by GCs are known to depend on their composition, route of administration, dose, and duration of treatment. However, the major pathogenic mechanisms of ARs are not clearly defined. There is evidence suggesting a role for imbalance between vasoconstriction and vasodilation, and its possible association with nitric oxide, prostanoids (prostaglandins, prostacyclin, and thromboxane), angiotensin II, vasopressin, arginine, endothelins, catecholamines, neuropeptides Y, and atrial natriuretic peptide. Enhanced oxidative stress, activated reninangiotensin system, escalating pressor response, metabolic syndrome, and sleep apnea also make their contribution. It could be ideal to discontinue GC treatment; but this is most commonly impossible because of a further disease exacerbation. In addition, it is necessary to carefully plan the choice of the dose, time, and route of administration of GCs and to evaluate each AR. The design of a GC with marked anti-inflammatory activity and insignificant metabolic effects must hold a central position in its researches.
Highlights
Glucocorticoids (GCs) are used to treat different inflammatory and autoimmune diseases due to their anti-inflammatory and immunoregulatory properties
GC may lead to the development of many adverse reactions (ARs): hypertension, diabetes mellitus, lipid metabolic disturbances, sleep apnea, osteoporosis, myopathy, and coagulation and fibrinolysis disorders, which are components of the Itsenko – Cushing syndrome
ARs induced by GCs are known to depend on their composition, route of administration, dose, and duration of treatment
Summary
I. Увеличение симпатической активности: повышенный синтез катехоламинов, экспрессия 1β-адренергических рецепторов [12, 13] II. ГК замедляют мета- показали активацию системы коагуляции Вторичному гиперпа- лобина) и повышенные уровни факторов VIII, IX, XII и XI ратиреозу и повышенной резорбции кости [26]. ГК тормозят остеобластогенез, снижая синтез коллаге- ны с ГК и полностью исчезают после хирургического лечена 1 типа и инсулиноподобного фактора роста, изменяя ния (при ЭнСК). ГК вызывают нарушения фибринолитичеанаболический эффект трансформирующего фактора роста ской системы и коагуляции: повышение синтеза/секреции β (ТФРβ), ингибируя Wnt-передачу и индуцируя апоптоз ос- PAI-1, уровня комплекса тромбин – антитромбин и плазтеобластов и остеоцитов [26]. ГК после трансплантации почки, получавших высокие дозы ГК, обнаружено снижение активности гликогенсинта-
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.